Related Experiment Video
Updated: May 16, 2025
Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier
Published on: April 26, 2016
A Review of Cryptotanshinone and its Nanoformulation in Cancer Therapy
Xin Liu1, Yahan Gao2, Fan Yang1
1School of Chemistry and Life Sciences, Suzhou University of Science and Technology, Suzhou, China.
Abstract:
Cancer, with a high incidence and mortality rate, has emerged as a major public health problem worldwide. Currently, new approaches, such as targeted therapy and immunotherapy, are giving hope to patients. However, drug resistance and adverse side effects are major barriers to cancer treatment. As a result, there is a greater focus on the development of cancer therapy strategies and medications with low toxicity and high efficacy. Cryptotanshinone (CTS), a diterpenoid quinone extracted from Salvia miltiorrhiza Bunge, exhibits a wide range of biological activities, including immunomodulatory, anti-inflammatory, and antitumor effects. In recent years, numerous studies have highlighted its significant antitumor properties, indicating potential clinical applications and development value. However, the clinical use of cryptotanshinone has been limited due to its poor water solubility and low bioavailability. To overcome these limitations, researchers are exploring new drug delivery systems, and novel formulation systems based on nanotechnology are being developed to improve the delivery and effectiveness of cryptotanshinone. In this review, we aim to consolidate the existing knowledge regarding the antitumor effects of cryptotanshinone and emphasize the latest advancements in its nanoformulation development. We hope to provide insights that will further improve the antitumor efficacy and clinical applicability of cryptotanshinone.
Insights
Cryptotanshinone (CTS) shows promise as an effective anticancer treatment. Nanotechnology-based formulations are being developed to enhance its poor solubility and bioavailability for improved clinical application.
Area of Science:
- Pharmacology
- Oncology
- Drug Delivery Systems
Background:
- Cancer remains a leading cause of mortality globally, necessitating novel therapeutic strategies.
- Existing treatments like targeted therapy and immunotherapy face challenges such as drug resistance and adverse effects.
- Cryptotanshinone (CTS), derived from Salvia miltiorrhiza Bunge, possesses demonstrated antitumor, anti-inflammatory, and immunomodulatory properties.
Purpose of the Study:
- To review the antitumor effects of Cryptotanshinone (CTS).
- To highlight recent advancements in nanoformulation development for CTS.
- To provide insights for enhancing CTS's clinical applicability and efficacy.
Main Methods:
- Literature review of studies on Cryptotanshinone (CTS).
- Analysis of research on nanoformulation strategies for improving CTS delivery.
- Consolidation of data on the antitumor properties and limitations of CTS.
Main Results:
- Cryptotanshinone (CTS) exhibits significant antitumor activity.
- Poor water solubility and low bioavailability limit the clinical use of CTS.
- Nanotechnology-based drug delivery systems show potential in overcoming CTS limitations.
Conclusions:
- Cryptotanshinone (CTS) is a promising compound for cancer therapy.
- Advancements in nanoformulations are crucial for improving CTS efficacy and bioavailability.
- Further research into CTS nanoformulations could lead to improved cancer treatment outcomes.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:15Drugs that Stabilize Microtubules